骨质疏鬆症治疗市场：依药物类型、给药途径、通路及地区划分

2025 年全球骨质疏鬆症治疗市场规模估计为 155.7 亿美元，预计到 2032 年将达到 210.6 亿美元，2025 年至 2032 年的复合年增长率为 4.4%。

数字。 2025 年骨质疏鬆症治疗市场占有率（按地区划分）

骨质疏鬆症是一种以骨量低和骨组织结构劣化为特征的疾病，导致骨骼变弱并增加骨折风险。该疾病已成为全球医学界关注的一大议题，尤其对老年族群而言。寿命延长、久坐的生活方式和营养摄取不足等因素是导致已开发国家和开发中国家骨质疏鬆症盛行率上升的主要原因。根据《Frontiers》杂誌发表的资料，全球有超过2亿人患有骨质疏鬆症。由于目前尚无治疗方法，终身药物治疗在治疗和预防骨折方面发挥重要作用。为了满足这项尚未满足的需求，全球骨质疏鬆症治疗市场在过去几十年来稳步成长。

市场动态

预计骨质疏鬆症高风险的老年人数量将增加，从而推动全球对骨质疏鬆症治疗的需求。根据联合国估计，到 2050 年，65 岁以上的人口预计将增加一倍以上。人们对骨质疏鬆症筛检和管理的认识不断提高、新产品的推出以及对高风险患者的诊断不断增加，将进一步推动市场成长。然而，重磅药物的专利到期和对学名药的偏好继续抑制市场的成长。同时，改善新兴国家的医疗保健服务也带来了庞大的机会。

研究的主要特点

• 本报告对全球骨质疏鬆症治疗市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模（十亿美元）和年复合成长率（CAGR%），以 2024 年为基准年。
• 它强调了各个领域的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
• 它还提供了对市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景以及主要企业采用的竞争策略的重要见解。
• 全球骨质疏鬆症治疗市场的主要企业简介是根据公司亮点、产品系列、关键亮点、绩效和策略等参数进行的。
• 主要企业包括 Teva Pharmaceutical Industries Ltd.、DAIICHI SANKYO COMPANY, LIMITED、Amgen Inc.、Dr. Reddy's Laboratories Ltd.、Viatris Inc.、Ligand Pharmaceuticals Incorporated、Eli Lilly and Company、Asahi Kasei Corporation、F. HM. Hr. 、Pfizer Inc.、Enzene Biosciences、Apotex Inc. 等。
• 本报告的见解将使负责人和公司经营团队能够就未来的产品发布、规模扩大、市场扩张和行销策略做出明智的决策。
• 全球骨质疏鬆症治疗市场迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过全球骨质疏鬆症治疗市场分析中使用的各种策略矩阵更轻鬆地做出决策。

目录

第一章 调查目的与前提条件

• 研究目标
• 先决条件
• 简称

第二章 市场展望

• 报告描述
  • 市场定义和范围
• 执行摘要
• 一致的机会图 (COM)

第三章市场动态、法规与趋势分析

• 市场动态
  • 驱动程式
  • 限制因素
  • 机会
• 影响分析
• 市场趋势
• 监管情景
• 製造商收益
• 收购和合作场景
• 产品发布/核准
• 资金筹措和投资
• PEST分析
• 波特的分析

4. 全球骨质疏鬆症治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 市场影响

5. 2020-2032 年全球骨质疏鬆症治疗市场（按药物类型划分）（十亿美元）

• 介绍
• 双磷酸盐
• 抑钙素，荷尔蒙疗法
• 选择性雌激素受体调节(SERM)
• 副甲状腺素相关蛋白 (PTHrP) 类似物
• 其他的

6. 2020 年至 2032 年全球骨质疏鬆症治疗市场（依给药途径划分）（十亿美元）

• 介绍
• 口服
• 注射
• 其他的

7. 2020-2032 年全球骨质疏鬆症治疗市场按分销管道划分（十亿美元）

• 介绍
• 医院药房
• 零售药局
• 网路药局

8. 2020 年至 2032 年全球骨质疏鬆症治疗市场（按地区划分）（十亿美元）

• 介绍
• 北美洲
• 拉丁美洲
• 欧洲
• 亚太地区
• 中东
• 非洲

第九章 竞争格局

• 公司简介
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

第 10 章分析师建议

• 兴衰
• 一致的机会地图

第 11 章 参考文献与调查方法

• 参考
• 调查方法

Global Osteoporosis Treatment Market is estimated to be valued at USD 15.57 Bn in 2025 and is expected to reach USD 21.06 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.4% from 2025 to 2032.

Figure. Osteoporosis Treatment Market Share (%), By Region 2025

Osteoporosis is a condition characterized by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures. The disease has become a major global healthcare concern, especially among the elderly population. Factors such as increasing life expectancy, sedentary lifestyles, and improper nutrition have contributed significantly to rising prevalence of osteoporosis across both developed and developing nations. According to data published by Frontiers, over 200 million people worldwide suffer from osteoporosis. With no curative treatment currently available, lifelong management through pharmacotherapy plays a crucial role in treatment and prevention of fractures. Global osteoporosis treatment market has witnessed steady growth over the past couple of decades to meet this unmet need.

Market Dynamics:

Growing geriatric population who are at high risk of osteoporosis is expected to boost demand for osteoporosis treatment drugs globally. According to the United Nations, the population aged 65 years and above is expected to more than double by 2050. Rising awareness about osteoporosis screening and management, new product launches, and increasing at-risk patient diagnosis are further propelling the market growth. However, patent expiries of blockbuster drugs and preference for generic drugs continue to restrain the market growth. Meanwhile, significant opportunities lie in emerging economies due to growing accessibility of healthcare.

Key Features of the Study:

• This report provides an in-depth analysis of the global osteoporosis treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global osteoporosis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Teva Pharmaceutical Industries Ltd., DAIICHI SANKYO COMPANY, LIMITED, Amgen Inc., Dr. Reddy's Laboratories Ltd., Viatris Inc., Ligand Pharmaceuticals Incorporated, Eli Lilly and Company, Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd, EffRx Pharmaceuticals SA, Novartis AG, Merck & Co., Inc., GSK plc., Pfizer Inc., Enzene Biosciences, Apotex Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global osteoporosis treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global osteoporosis treatment market.

Detailed Segmentation-

• By Drug Type:
  • Bisphosphonates
  • Calcitonin, Hormone Therapy
  • Selective Estrogen Receptor Modulators (SERMs)
  • Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Others
• By Route of Administration:
  • Oral
  • Injectable
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Teva Pharmaceutical Industries Ltd.
  • DAIICHI SANKYO COMPANY, LIMITED
  • Amgen Inc.
  • Reddy's Laboratories Ltd.
  • Viatris Inc.
  • Ligand Pharmaceuticals Incorporated
  • Eli Lilly and Company
  • Asahi Kasei Corporation
  • Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Osteoporosis Treatment Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Osteoporosis Treatment Market, By Drug Type, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Bisphosphonates
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Calcitonin, Hormone Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Selective Estrogen Receptor Modulators (SERMs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parathyroid Hormone-Related Protein (PTHrP) Analog
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Osteoporosis Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Injectable
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Osteoporosis Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2020 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Osteoporosis Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2020-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • DAIICHI SANKYO COMPANY, LIMITED
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Amgen Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Reddy's Laboratories Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Viatris Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Ligand Pharmaceuticals Incorporated
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd
  • EffRx Pharmaceuticals SA
  • Novartis AG
  • Merck & Co., Inc.
  • GSK plc.
  • Pfizer Inc.
  • Enzene Biosciences
  • Apotex Inc.

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact

"